BUUU Group Limited
BUUUBUUU Group Limited's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
The sharpest disagreement: the price moved +489.9% in a year while annual EPS moved −16.7% — the difference is re-rating, and re-rating has to be repaid with earnings.
The price is between stages. Underneath, the last four quarters read mixed. What settles it: whether earnings grow into a price that has already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
BUUU Group Limited trades at $46.0, between stages. That is +167.7% against its own 200-day average. It sits at 100% of a 52-week range of $7 to $46. On relative strength it has been ahead of the S&P 500 on a trailing-13-week view for 17 straight weeks.
Today the stock is between stages. At $46.0 it trades +167.7% versus its 200-day average and sits at 100% of its 52-week range ($7–$46).
Against the market, two honest reads. Cumulative: over the last 1.1 years the stock moved +1,014% while the S&P 500 moved +17% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 17 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.
P/E does not price BUUU Group Limited — earnings are negative, so there is no multiple to rank against its own history. The revenue and margin lines below are where a turn, when it comes, would show first. On sales the market values BUUU Group Limited at 100.0× its FY25 revenue of $0.0 B.
With earnings negative, P/E does not price — there is no multiple to rank against its own history. The revenue and margin lines below are where the turn, when it comes, will show first.
🚨 Why the multiple sits where it does: over the past year annual EPS moved −16.7% against a +489.9% price move — the price outran earnings, pushing the multiple UP its own range.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
BUUU Group Limited reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +0.0% | — | — | — |
| EPS | −16.7% | — | — | — |
| Stock price | +489.9% | — | — | — |
4-Factor Sector Score
48.7/100 — rank 29 of 30 in Specialty Business Services · 32% evidence confidence · provisional, ranked below fully-evidenced peers
BUUU Group Limited scores 48.7 out of 100 against the 30 companies it is compared with in Specialty Business Services, ranking 29. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
The four contributions add to the total exactly: 16 + 7.2 + 8.5 + 17 = 48.7. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
BUUU Group Limited reported $0.0 B of revenue in the Dec 25 quarter. The last full year, FY25, came in at $0.0 B. The last four reported quarters add to $0.0 B. A multi-year compound rate is not shown because the annual history behind it is too short to compute one honestly.
FY25 revenue came in at $0.0 B (+0.0% on the year). The latest quarter (Dec 25) printed $0.0 B, null year on year.
Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
A clean operating margin is not in our numbers for BUUU Group Limited — its accounts do not report the operating-profit line this section reads, which is common for lenders and holding companies. The sections above and below carry the readings this company's filings do support.
This company's accounts do not report the operating-profit line this section reads — common for lenders and holding companies classified outside the financial bucket. The revenue and net-profit sections are the cleaner reads for BUUU Group Limited.
Why: the numbers show the operating margin move clearly, but the cost lines behind it sit below what we hold — so we state the move without inventing its driver.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
BUUU Group Limited earned $0.0 B of net profit in the Dec 25 quarter. Full-year FY25 profit was $0.0 B. The same quarter a year earlier earned $0.0 B.
Dec 25 profit was $0.0 B, null year on year. On the full year, FY25 printed $0.0 B (null).
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
BUUU Group Limited's cash-flow history is too thin to judge how much reported profit converts into cash. In FY25 that was $0.0 B of operating cash against $0.0 B of profit. After $0.0 B of capital spending, $0.0 B was left as free cash. Cash resolution here is annual, because quarterly cash statements are not published.
FY25: operating cash of $0.0 B against reported profit of $0.0 B, leaving free cash of $0.0 B after $0.0 B of capital spending.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
BUUU Group Limited does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $0.0 B over the last 3 years. Averaged over those years that is 0.0% of FY25 revenue a year.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of $0.0 B over the last 3 fiscal years.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Returns on capital ROE is the profit the business earns on the money invested in it — the single best test of whether growth creates value or just size.
An annual ROE ladder is not held for BUUU Group Limited.
We do not hold an annual ROE series for BUUU Group Limited. Its filings carry the return lines we would need as blanks rather than numbers, so this page does not estimate one. The revenue, margin, cash-flow and ownership sections are the reads we stand behind.
Dividend
BUUU Group Limited pays no dividend. Across the last 5 reported quarters it has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings rather than distribute them, which makes the cash-flow and reinvestment sections the place that cash shows up.
BUUU Group Limited does not currently pay a dividend. Across the last 5 reported quarters the company has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings instead of distributing them.
Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.
Debt-to-equity is 0.10 at the latest reading — effectively unlevered; a full borrowings history is not in our numbers.
We hold only the latest reading here: a debt-to-equity of 0.10 — the balance sheet is effectively unlevered, so the returns above are earned, not borrowed. A year-by-year borrowings ladder is not in our numbers for this stock, so we say that rather than draw a chart we cannot support.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
0.2% of BUUU Group Limited's tradable float is currently sold short — the crowd is not positioned against this stock. At typical trading volumes those positions would take about 0.1 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
The latest reading: 0.2% of the float is sold short, and at typical trading volumes it would take about 0.1 days to buy those positions back. The crowd is not positioned against this stock. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.
Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
BUUU Group Limited: the Z-score reads 45.58. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 45.58 sits well clear of the distress zone — the balance sheet is not the risk here.
The safety line in one sentence: the Z-score reads 45.58.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1ABM Industries IncorporatedABM | 63.2/100Mixed-positive evidence85% evidence | BREAKING OUT | 21.4/35 Revenue 6.5% · PAT 100% · OPM change -0.1 pp 95% evidence | 11.1/25 ROCE 2.1% · OPM 3.8% 76% evidence | 15.4/20 P/E 15.7× · PEG 0.38 65% evidence | 15.3/20 RS sector 2% · RS bench 7.2% · 1Y 11.8%9 of 12 weeks ahead 100% evidence |
| Exact sum: 21.4 + 11.1 + 15.4 + 15.3 = 63.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2First Advantage CorporationFA | 61.2/100Mixed-positive evidence64% evidence | LEADER | 24.3/35 Revenue 53.4% · PAT — · OPM change 6.6 pp 62% evidence | 9.3/25 ROCE 0.9% · OPM 8.7% 76% evidence | 8.6/20 P/E 294× · PEG — 15% evidence | 19.0/20 RS sector 26.2% · RS bench 32% · 1Y 40.7%12 of 12 weeks ahead 100% evidence |
| Exact sum: 24.3 + 9.3 + 8.6 + 19 = 61.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Cintas CorporationCTAS | 58.4/100Mixed-positive evidence85% evidence | BREAKING OUT | 24.1/35 Revenue 8.9% · PAT 10.4% · OPM change 0.8 pp 95% evidence | 16.9/25 ROCE 8.4% · OPM 23.2% 76% evidence | 6.1/20 P/E 34.9× · PEG 3.08 65% evidence | 11.3/20 RS sector -5.8% · RS bench -0.9% · 1Y -0.3%10 of 12 weeks ahead 100% evidence |
| Exact sum: 24.1 + 16.9 + 6.1 + 11.3 = 58.4 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 4CBIZ, Inc.CBZ | 58.0/100Mixed-positive evidence85% evidence | BREAKING OUT | 15.6/35 Revenue 14.4% · PAT 9.2% · OPM change -3.8 pp 95% evidence | 8.5/25 ROCE 0.8% · OPM 5% 76% evidence | 15.2/20 P/E 15× · PEG 0.65 65% evidence | 18.7/20 RS sector 14.2% · RS bench 20.5% · 1Y 1.5%12 of 12 weeks ahead 100% evidence |
| Exact sum: 15.6 + 8.5 + 15.2 + 18.7 = 58 · Decision use: Price leads the evidence: RS versus the benchmark is 20.5%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 5AramarkARMK | 56.5/100Thin evidence · provisional58% evidence | LEADER | 19.7/35 Revenue — · PAT — · OPM change 0.6 pp 45% evidence | 12.1/25 ROCE 2.1% · OPM 4.5% 76% evidence | 9.8/20 P/E 32× · PEG — 15% evidence | 14.9/20 RS sector 13.4% · RS bench 18.6% · 1Y 53.2%10 of 12 weeks ahead 100% evidence |
| Exact sum: 19.7 + 12.1 + 9.8 + 14.9 = 56.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 6Maximus, Inc.MMS | 54.7/100Mixed-positive evidence81% evidence | TURNING | 18.6/35 Revenue -1.5% · PAT 23.9% · OPM change 0.2 pp 83% evidence | 14.4/25 ROCE 4.2% · OPM 11.4% 76% evidence | 16.3/20 P/E 9.6× · PEG 0.29 65% evidence | 5.4/20 RS sector -30.1% · RS bench -26.1% · 1Y -35.3%0 of 12 weeks ahead 100% evidence |
| Exact sum: 18.6 + 14.4 + 16.3 + 5.4 = 54.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Thomson Reuters CorporationTRI | 54.3/100Mixed-positive evidence85% evidence | BREAKING OUT | 24.0/35 Revenue 7% · PAT 5% · OPM change 4.2 pp 95% evidence | 15.4/25 ROCE 3.9% · OPM 28.6% 76% evidence | 5.6/20 P/E 21.7× · PEG 4.61 65% evidence | 9.3/20 RS sector -18.6% · RS bench -13.8% · 1Y -37.8%6 of 12 weeks ahead 100% evidence |
| Exact sum: 24 + 15.4 + 5.6 + 9.3 = 54.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Quad/Graphics, Inc.QUAD | 53.3/100Thin evidence · provisional52% evidence | LEADER | 17.1/35 Revenue — · PAT — · OPM change -0.1 pp 45% evidence | 9.1/25 ROCE 2.2% · OPM 3% 76% evidence | 11.0/20 P/E 13.4× · PEG — 15% evidence | 16.1/20 RS sector 19% · RS bench 24.2% · 1Y 46.6%10 of 12 weeks ahead 70% evidence |
| Exact sum: 17.1 + 9.1 + 11 + 16.1 = 53.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 9Copart, Inc.CPRT | 52.7/100Mixed-positive evidence85% evidence | TURNING | 18.3/35 Revenue 1.1% · PAT 5% · OPM change 0.2 pp 95% evidence | 20.7/25 ROCE 18.9% · OPM 37.5% 76% evidence | 6.6/20 P/E 20.5× · PEG 3.47 65% evidence | 7.1/20 RS sector -24.1% · RS bench -19.8% · 1Y -32.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 18.3 + 20.7 + 6.6 + 7.1 = 52.7 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 10Global Payments Inc.GPN | 51.3/100Mixed-positive evidence75% evidence | BREAKING OUT | 11.3/35 Revenue 32.5% · PAT -157.1% · OPM change -12.3 pp 95% evidence | 13.7/25 ROCE 4.2% · OPM 16.1% 76% evidence | 11.5/20 P/E -21.2× · PEG — 15% evidence | 14.8/20 RS sector -0.1% · RS bench 5% · 1Y -0.1%11 of 12 weeks ahead 100% evidence |
| Exact sum: 11.3 + 13.7 + 11.5 + 14.8 = 51.3 · Decision use: Price leads the evidence: RS versus the benchmark is 5%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 11Dolby Laboratories, Inc.DLB | 49.4/100Thin evidence · provisional58% evidence | BREAKING OUT | 16.7/35 Revenue — · PAT — · OPM change -0.7 pp 45% evidence | 13.3/25 ROCE 1.2% · OPM 28.5% 76% evidence | 10.1/20 P/E 22.8× · PEG — 15% evidence | 9.3/20 RS sector -15.8% · RS bench -11.2% · 1Y -17.9%6 of 12 weeks ahead 100% evidence |
| Exact sum: 16.7 + 13.3 + 10.1 + 9.3 = 49.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 12Cass Information Systems, Inc.CASS | 48.6/100Thin evidence · provisional58% evidence | LEADER | 17.3/35 Revenue — · PAT — · OPM change -7.1 pp 45% evidence | 4.5/25 ROCE -3.2% · OPM -37% 76% evidence | 10.7/20 P/E 18.5× · PEG — 15% evidence | 16.1/20 RS sector 6.5% · RS bench 11.6% · 1Y 33.3%10 of 12 weeks ahead 100% evidence |
| Exact sum: 17.3 + 4.5 + 10.7 + 16.1 = 48.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 13Eastman Kodak CompanyKODK | 48.6/100Thin evidence · provisional58% evidence | ASLEEP | 20.2/35 Revenue 4.4% · PAT -317.5% · OPM change 4.9 pp 62% evidence | 6.7/25 ROCE -0.1% · OPM -0.4% 76% evidence | 11.2/20 P/E 12.9× · PEG — 15% evidence | 10.5/20 RS sector -2.8% · RS bench 1.6% · 1Y 52.2%0 of 12 weeks ahead 70% evidence |
| Exact sum: 20.2 + 6.7 + 11.2 + 10.5 = 48.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 14AZZ Inc.AZZ | 47.8/100Mixed-negative evidence85% evidence | ASLEEP | 17.0/35 Revenue 5.7% · PAT -23.9% · OPM change 0.7 pp 95% evidence | 13.8/25 ROCE 3.9% · OPM 17.2% 76% evidence | 11.0/20 P/E 20.7× · PEG 1.43 65% evidence | 6.0/20 RS sector -7% · RS bench -2.7% · 1Y 16.5%1 of 12 weeks ahead 100% evidence |
| Exact sum: 17 + 13.8 + 11 + 6 = 47.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Transcat, Inc.TRNS | 45.4/100Mixed-negative evidence75% evidence | ASLEEP | 13.1/35 Revenue 18.6% · PAT -61.5% · OPM change -4.2 pp 83% evidence | 9.8/25 ROCE 1.1% · OPM 4.8% 76% evidence | 10.0/20 P/E 125.1× · PEG 1.35 65% evidence | 12.5/20 RS sector 0.1% · RS bench 4.8% · 1Y 10.9%6 of 12 weeks ahead 70% evidence |
| Exact sum: 13.1 + 9.8 + 10 + 12.5 = 45.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16UL Solutions Inc.ULS | 44.2/100Mixed-negative evidence81% evidence | ASLEEP | 22.2/35 Revenue 6.9% · PAT 4.2% · OPM change 2.7 pp 83% evidence | 16.1/25 ROCE 6.7% · OPM 18.2% 76% evidence | 4.9/20 P/E 50.1× · PEG 4 65% evidence | 1.0/20 RS sector -31.1% · RS bench -27.7% · 1Y -5.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 22.2 + 16.1 + 4.9 + 1 = 44.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17UniFirst CorporationUNF | 44.1/100Mixed-negative evidence85% evidence | FADING | 10.0/35 Revenue 1.4% · PAT -24.3% · OPM change -4.3 pp 95% evidence | 10.1/25 ROCE 0.9% · OPM 3.6% 76% evidence | 11.5/20 P/E 41.9× · PEG 1.23 65% evidence | 12.5/20 RS sector 3% · RS bench 7.5% · 1Y 58%5 of 12 weeks ahead 100% evidence |
| Exact sum: 10 + 10.1 + 11.5 + 12.5 = 44.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18Cimpress plcCMPR | 43.3/100Thin evidence · provisional58% evidence | ASLEEP | 16.2/35 Revenue — · PAT — · OPM change 0.4 pp 45% evidence | 11.2/25 ROCE 4.9% · OPM 5.5% 76% evidence | 10.0/20 P/E 26.8× · PEG — 15% evidence | 5.9/20 RS sector -8.7% · RS bench -4.4% · 1Y 30.8%4 of 12 weeks ahead 100% evidence |
| Exact sum: 16.2 + 11.2 + 10 + 5.9 = 43.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 19RB Global, Inc.RBA | 43.0/100Mixed-negative evidence81% evidence | ASLEEP | 20.2/35 Revenue 9.5% · PAT 7.3% · OPM change 0.5 pp 83% evidence | 15.6/25 ROCE 7.5% · OPM 17.6% 76% evidence | 4.4/20 P/E 44.1× · PEG 7.47 65% evidence | 2.8/20 RS sector -27% · RS bench -23.2% · 1Y -29.1%0 of 12 weeks ahead 100% evidence |
| Exact sum: 20.2 + 15.6 + 4.4 + 2.8 = 43 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20Amentum Holdings, Inc.AMTM | 39.4/100Thin evidence · provisional58% evidence | BASING | 19.5/35 Revenue — · PAT — · OPM change 1.4 pp 45% evidence | 8.7/25 ROCE 1.6% · OPM 4.3% 76% evidence | 9.3/20 P/E 45.1× · PEG — 15% evidence | 1.9/20 RS sector -31.5% · RS bench -27.9% · 1Y -11.1%0 of 12 weeks ahead 100% evidence |
| Exact sum: 19.5 + 8.7 + 9.3 + 1.9 = 39.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 21TIC Solutions, Inc.TIC | 38.0/100Thin evidence · provisional53% evidence | FADING | 14.9/35 Revenue — · PAT — · OPM change -2 pp 39% evidence | 4.7/25 ROCE -1% · OPM -6% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 8.4/20 RS sector -17.7% · RS bench -13.1% · 1Y -38.5%4 of 12 weeks ahead 100% evidence |
| Exact sum: 14.9 + 4.7 + 10 + 8.4 = 38 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 22Target Hospitality Corp.TH | 37.9/100Mixed-negative evidence64% evidence | ASLEEP | 9.2/35 Revenue -7.4% · PAT -197.8% · OPM change -18.2 pp 62% evidence | 5.7/25 ROCE -2.9% · OPM -19.7% 76% evidence | 9.1/20 P/E 71.2× · PEG — 15% evidence | 13.9/20 RS sector 40.3% · RS bench 45.6% · 1Y 116.6%6 of 12 weeks ahead 100% evidence |
| Exact sum: 9.2 + 5.7 + 9.1 + 13.9 = 37.9 · Decision use: Price leads the evidence: RS versus the benchmark is 45.6%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 23LegalZoom.com, Inc.LZ | 35.0/100Mixed-negative evidence75% evidence | TURNING | 10.6/35 Revenue 12.9% · PAT -60% · OPM change -3.6 pp 83% evidence | 8.3/25 ROCE 1.5% · OPM 1.3% 76% evidence | 12.2/20 P/E 94.5× · PEG 0.93 65% evidence | 3.9/20 RS sector -30.3% · RS bench -26.2% · 1Y -44.7%6 of 12 weeks ahead 70% evidence |
| Exact sum: 10.6 + 8.3 + 12.2 + 3.9 = 35 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24BrightView Holdings, Inc.BV | 33.8/100Adverse evidence65% evidence | ASLEEP | 12.1/35 Revenue 0% · PAT 2.2% · OPM change -1.1 pp 83% evidence | 7.2/25 ROCE 0.6% · OPM 2.3% 76% evidence | 8.8/20 P/E 103.1× · PEG — 15% evidence | 5.7/20 RS sector -23.9% · RS bench -19.9% · 1Y -18.7%5 of 12 weeks ahead 70% evidence |
| Exact sum: 12.1 + 7.2 + 8.8 + 5.7 = 33.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 25Resolute Holdings Management, Inc.RHLD | 33.0/100Adverse evidence62% evidence | FADING | 11.1/35 Revenue 82.2% · PAT -83.2% · OPM change -26 pp 83% evidence | 7.3/25 ROCE -0.2% · OPM -1.4% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 4.6/20 RS sector -27.2% · RS bench -23.4% · 1Y 71.4%5 of 12 weeks ahead 70% evidence |
| Exact sum: 11.1 + 7.3 + 10 + 4.6 = 33 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 26BlackSky Technology Inc.BKSY | 28.1/100Thin evidence · provisional55% evidence | BASING | 9.1/35 Revenue -9.3% · PAT — · OPM change -48.7 pp 62% evidence | 3.8/25 ROCE -6.5% · OPM -89.2% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 5.2/20 RS sector -25% · RS bench -21.6% · 1Y 2.5%0 of 12 weeks ahead 70% evidence |
| Exact sum: 9.1 + 3.8 + 10 + 5.2 = 28.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 27Spire Global, Inc.SPIR | 24.8/100Adverse evidence64% evidence | ASLEEP | 7.2/35 Revenue -36% · PAT — · OPM change -36.7 pp 62% evidence | 3.1/25 ROCE -30.4% · OPM -155.2% 76% evidence | 11.4/20 P/E 8.3× · PEG — 15% evidence | 3.1/20 RS sector -20.5% · RS bench -17.1% · 1Y 9.1%0 of 12 weeks ahead 100% evidence |
| Exact sum: 7.2 + 3.1 + 11.4 + 3.1 = 24.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 28RELX PLCRELX | 54.5/100Thin evidence · provisional44% evidence | TURNING | 19.3/35 Revenue — · PAT — · OPM change — 16% evidence | 15.8/25 ROCE 9.3% · OPM — 61% evidence | 10.6/20 P/E 19.2× · PEG — 15% evidence | 8.8/20 RS sector -17.9% · RS bench -13.4% · 1Y -27.1%3 of 12 weeks ahead 100% evidence |
| Exact sum: 19.3 + 15.8 + 10.6 + 8.8 = 54.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 29BUUU Group Limitedthis pageBUUU | 48.7/100Thin evidence · provisional32% evidence | LEADER | 16.0/35 Revenue — · PAT — · OPM change — 9% evidence | 7.2/25 ROCE -13.1% · OPM — 46% evidence | 8.5/20 P/E 543.3× · PEG — 15% evidence | 17.0/20 RS sector 166.1% · RS bench 175% · 1Y 489.9%12 of 12 weeks ahead 70% evidence |
| Exact sum: 16 + 7.2 + 8.5 + 17 = 48.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 30Rentokil Initial plcRTO | 41.1/100Thin evidence · provisional43% evidence | BASING | 18.1/35 Revenue — · PAT — · OPM change — 12% evidence | 12.4/25 ROCE 1.8% · OPM — 61% evidence | 9.9/20 P/E 30.3× · PEG — 15% evidence | 0.7/20 RS sector -33.2% · RS bench -29.8% · 1Y -10.2%0 of 12 weeks ahead 100% evidence |
| Exact sum: 18.1 + 12.4 + 9.9 + 0.7 = 41.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is BUUU Group Limited's stock price today?
BUUU Group Limited trades at $46.0, +489.9% over the past year. The company is valued at $1.0 B. The stock sits at the very top of its 52-week range ($7–$46), +167.7% versus its 200-day average. Against the S&P 500 it has been ahead on a trailing-13-week view for 17 weeks. — as of 17 September 2026.
What were BUUU Group Limited's latest quarterly results?
BUUU Group Limited reported revenue of $0.0 B and net profit of $0.0 B for the Dec 25 quarter. — as of 17 September 2026.
What is BUUU Group Limited's revenue?
BUUU Group Limited reported revenue of $0.0 B in the Dec 25 quarter. For the full FY25 fiscal year, revenue was $0.0 B (+0.0%). — as of 17 September 2026.
What is BUUU Group Limited's profit?
BUUU Group Limited earned $0.0 B of net profit in the Dec 25 quarter. Full-year FY25 profit was $0.0 B. — as of 17 September 2026.
What is BUUU Group Limited's market cap?
BUUU Group Limited's market capitalisation is $1.0 B at a stock price of $46.0. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 17 September 2026.
Does BUUU Group Limited pay a dividend?
No — BUUU Group Limited has declared no dividend per share in any of its last 5 reported quarters, so there is no payout history and no yield to quote. That is a reading of the filed statements, not an estimate. — as of 17 September 2026.
How is BUUU Group Limited performing?
BUUU Group Limited's latest readings are below. Against the S&P 500 it has been ahead on a trailing-13-week view for 17 weeks. This describes what the data did, not a rating. — as of 17 September 2026.
Is BUUU Group Limited beating the market?
On recent form, yes — BUUU Group Limited has been ahead of the S&P 500 on a trailing-13-week view for 17 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 1.1 years the stock moved +1,014% against the S&P 500's +17% — ahead of the index over the full window. — as of 17 September 2026.
Will BUUU Group Limited's stock price go up?
This page publishes no price forecast for BUUU Group Limited. What it measures instead: the stock price is $46.0. Direction is not something this site claims to know. — as of 17 September 2026.
Is the market betting against BUUU Group Limited?
No — short interest is 0.2% of BUUU Group Limited's tradable float, about 0.1 days to cover at typical volumes. That is a low reading: the crowd is not positioned against this stock. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 17 September 2026.
Does BUUU Group Limited have too much debt?
No — BUUU Group Limited's debt-to-equity is 0.10. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. The returns on this page are earned, not borrowed — as of 17 September 2026.
What is BUUU Group Limited's capex?
BUUU Group Limited spent $0.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $0.0 B. — as of 17 September 2026.
What is BUUU Group Limited's cash flow?
BUUU Group Limited generated $0.0 B of operating cash flow in FY25 and $0.0 B of free cash flow after $0.0 B of capital spending. Reported profit that year was $0.0 B, so operating cash ran ahead of profit. — as of 17 September 2026.
How financially safe is BUUU Group Limited?
On the balance sheet, the Z-score reads 45.58 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That sits well clear of trouble. — as of 17 September 2026.
Where is BUUU Group Limited in its business cycle?
BUUU Group Limited's FY25 operating margin was 0.0%, against a 2-year band of 0.0%–0.0%: the low end of its own band, which is where recoveries start when they come. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 17 September 2026.
What could break the BUUU Group Limited story?
The sharpest disagreement: the price moved +489.9% in a year while annual EPS moved −16.7% — the difference is re-rating, and re-rating has to be repaid with earnings. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 17 September 2026.
Is BUUU Group Limited a stock worth studying right now?
This is not investment advice. The machine read: BUUU Group Limited's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: whether earnings grow into a price that has already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 17 September 2026.
Not SEBI Registered !! Not Investment advice !!